Lasa Supergenerics rises nearly 2 per cent on adding Oxyclozanide to its product portfolio
The manufacturer of veterinary & human APIs, Lasa Supergenerics announced today the launch of Oxyclozanide in its product portfolio for the domestic as well as the export markets.
Oxyclozanide is an Anthelmintic, which is used in the treatment and control of Fascioliasis, a topical worm infection in ruminants mainly, domestic animals such as cattle, sheep & goats.
Lasa is setting up capacity in a brownfield expansion at its Chiplun unit (Maharashtra) with a total capacity of 250 MT and is funding the required Capex via internal accruals. Besides, its production would commence in August 2021.
The product is estimated to have huge demand while the management is confident of having a strong order book from the time its production commences. The company already has export approvals for Oxyclozanide in several regions, where it plans to export.
At 2.34 pm on Wednesday, the company’s stock was trading at Rs 44.30, up by 1.78 per cent on BSE.